Ori C613
Alternative Names: Ori-C613Latest Information Update: 16 Sep 2022
Price :
$50 *
At a glance
- Originator OriCell Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Sep 2022 Ori C613 is available for licensing as of 07 Sep 2022. https://www.oricell.com/en/Contact/
- 07 Sep 2022 Oricell Therapeutics has patent protection for Ori®CAR CAR-T platform before September 2022 (OriCell Therapeutics website, September 2022)
- 07 Sep 2022 Preclinical trials in Solid tumours in China (Parenteral) before September 2022 (Oricell Therapeutics pipeline, September 2022)